KUNMING, China, July 24 /Xinhua-PRNewswire/ -- China Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN) ("China Shenghuo" or "the Company"), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People’s Republic of China ("PRC"), today announced that it has retained Grayling Global to lead a strategic communications program (“the IR program”) to shareholders, the investment community and financial media.
"Grayling Global was selected to represent China Shenghuo after a thorough review of numerous candidates,” said Mr. Guihua Lan, the Chairman and CEO of China Shenghuo. “The firm’s longstanding investor relations track record in the healthcare sector, its keen understanding of the Chinese marketplace and its strong ability to enhance shareholder value for clients were the key reasons we selected them to assist us in our investor relations efforts. We believe Grayling’s effective communications programs and impressive reputation of developing long-term relationships with the investment community will enable China Shenghuo to generate investor awareness and visibility.”
Grayling Global, a subsidiary of Huntsworth PLC (LSE: HNT), is headquartered in London, with offices in New York, Brussels, Bangkok, Singapore, Madrid, Moscow, Tel Aviv, Shanghai, Istanbul, Los Angeles, Sacramento, Dublin, Edinburgh, Cardiff, Bristol, and Birmingham. The firm has over 200 consultants, focusing on first-class delivery in public affairs, public relations, investor relations and events management.
About China Shenghuo
Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the "Company") is a specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd. ("Kunming Shenghuo"), it owns thirty SFDA (State Food and Drug Administration) approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn .
Forward Looking Statements
This press release may contain certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management s current expectations. Such factors include, but are not limited to, the Company s reliance on one supplier for Sanchi, ability to develop and market new products, ability to establish and maintain a strong brand, continued maintenance of certificates, permits and licenses required to conduct business in China, protection of company’s intellectual property rights, market acceptance of the company s products, changes in the laws of the People s Republic of China that affect the company s operations, the company s ability to obtain all necessary government certifications and/or licenses to open and operate retail specialty counters to offer its cosmetic products and conduct the company s business, cost of complying with current and future governmental regulations and the impact of any changes in the regulations on the Company’s operations and other factors detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.